Z
Zhengduo Yang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 11
Citations - 858
Zhengduo Yang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 9, co-authored 11 publications receiving 724 citations. Previous affiliations of Zhengduo Yang include Anhui Medical University.
Papers
More filters
Journal ArticleDOI
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
TL;DR: Current literature is summarized, the potential importance of STAT3 as a novel target for cancer prevention and ofSTAT3 inhibitors as effective chemopreventive agents are discussed and the lag in developing effective STAT3 inhibitors is summarized.
Journal ArticleDOI
TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway
Xiaojing Meng,Chunqing Cai,Jiguo Wu,Shaoxi Cai,Changsheng Ye,Haiyang Chen,Zhengduo Yang,Hongqiang Zeng,Qiang Shen,Fei Zou +9 more
TL;DR: The results suggest that TRPM7 regulates migration and invasion of metastatic breast cancer cells via MAPK pathway.
Journal ArticleDOI
Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents
Haijun Chen,Zhengduo Yang,Chunyong Ding,Lili Chu,Yusong Zhang,Kristin Terry,Huiling Liu,Qiang Shen,Jia Zhou +8 more
TL;DR: Compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo, indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.
Journal ArticleDOI
Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.
Chunyong Ding,Yusong Zhang,Yusong Zhang,Haijun Chen,Zhengduo Yang,Christopher Wild,Lili Chu,Huiling Liu,Qiang Shen,Jia Zhou +9 more
TL;DR: These new analogues obtained by rationally modifying the natural product have been demonstrated not only to significantly induce the apoptosis and suppress growth of triple-negative MDA-MB-231 breast cancer both in vitro and in vivo but also effective against drug-resistant ER-positive MCF-7 clones.
Journal ArticleDOI
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy
Haijun Chen,Zhengduo Yang,Chunyong Ding,Lili Chu,Yusong Zhang,Kristin Terry,Huiling Liu,Qiang Shen,Jia Zhou +8 more
TL;DR: The fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents by utilizing six privileged fragments from known STAT3 inhibitors are reported, indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy.